TRANSDERMAL THERAPEUTIC SYSTEMS – AN INNOVATIVE METHOD TO PREVENT THE FORMATION OF KELOIDS
Keywords:scar tissue (scar), keloid scars (keloids), pathological scarring, scar treatment methods, transdermal therapeutic systems
Modern medicine has achieved significant results in the development of techniques to avoid surgeries. However, surgical methods are still one of the main tools for treating pathologies in the human body. Plastic surgery and cosmetology are gaining popularity every year, and sports injuries require the use of combined treatment methods, but any such intervention leads to the risk of keloids. The younger the person, the higher the likelihood of developing a keloid, due to the high degree of elasticity of the skin at an earlier age, which is prone to scarring than in older people. Women are at higher risk of developing keloids than men because their skin is more elastic. Thus, children and young women are most at risk of keloid formation, both as a result of physiological processes of skin scarring and preference for plastic surgery, cosmetic procedures and other methods of correction. In world pharmaceutical practice, there are not enough existing ways to prevent the development of keloid. It is necessary to conduct research on the selection of a fundamentally new structural basis for a transdermal therapeutic system containing the most effective and safe compounds of the regenerating and antioxidant mechanisms of action (vitamins and other biologically active compounds) from the point of view of preventing the formation of keloids, which will help in solving the problem of not only preventing the formation of keloids in dermis, but also its subsequent growth and exit to the surface layers of the skin.
Voronkov AB, Stepanova EF, Zhidkova YuYu, Gamzeleva OYu Modern approaches to pharmacological correction of pathological scars (Review). Fundamental research. 2014;3:301-8.
Clinical protocol for the diagnosis and treatment of patients with cicatricial skin lesions. Approved at the meeting of the Sections of the Russian Dental Association «Association of Oral and Maxillofacial Surgeons and Dental Surgeons» on April 21, 2014.
Ozerskaya OS Skin scars and their dermatocosmetological correction. SPb: OFO, publishing house «Art of Russia»;2007.
Hartman-Adams J. Management of keloid and hypertrophic scars. Am. Fam. Physician. 2009;80(3):253-6.
Al-Attar A, Mess S, Thomassen JM, Kauffman CL, Davison SP. Keloid pathogenesis and treatment. Plast Reconstr. Surg. 2006;117:286-300.
Kovaleva LN. Modern differentiated approach to complex treatment and prevention of skin scars of different etiology. Dermatovenereology. Cosmetology. Sexopathology. 2016;1-4:188-98.
Filippova OV, Krasnogorskiy IV. Structural changes in scar tissue in children at various stages of scar maturation and against the background of collagenolytic therapy. Clinical Dermatology and Venereology. 2013;1:1-7.
Bran GM, Goessler UR, Hormann K, Riedel F, Sadick H. Keloids: current concepts of pathogenesis. Int J Mol Med. 2009;24(3):283-93.
Karapetyan GE, Pakhomova RA, Kochetova LV, Solovieva NS, Nazaryants YuA, Vasilenya ES et al. Treatment of hypertrophic and keloid scars. Fundamental research. 2013;3:70-3.
Kenneth A Arndt, editor. Scar correction. M .: Reed Elsiver;2009.
Michelle C et al.. Current Concepts in the etiology and treatment of keloids. Facial Plastic Surgery. 2012;28:504-12.
Ogawa R. The most current algorithms for the treatment and prevention of hypertrophic scars and keloids. Plast. Reconstr. Surg. 2010;125(2):557-68.
Fedotov VP, Rybalkin SB, Romantsov MG. Essays on immunocorrection in dermatovenerology: A manual for doctors. SPb;2005.
Chub SG. Modern trends in the evolution of methods for the prevention and treatment of pathological scarring. Bulletin of Aesthetic Medicine. 2009;8(2):6-22.
Durani P, Bayat A. Levels of evidence for the treatment of keloid disease. J. Plast. Reconstr. Aesthet. Surg. 2008;61:4-17.
Belousov AE. Essays on plastic surgery. Scars and their correction. Vol. 1. SPb .: Publishing house «Commander-SPB»; 2005.
Flaks GA, Taganov AV, Gladko VV, Pismenkova AV, Mordovtseva VV. Comparative assessment of various methods of treatment of keloid and hypertrophic scars. Experimental and Clinical Dermatocosmetology. 2012;3:43-6.
Roseborough IE, Grevios MA, Lee R. Preventionand treatmentof excessive dermal scarring. J. Natl. Med. Ass. 2004;96(1):108-16.
Sharobaro VI, Moroz VYu, Yudenich AA, Vaganova NA, Grechishnikov MI, Vaganov NV. Plastic surgery on the face and neck after burns. Clinical practice. 2013;4 (16):17-21.
Kolokolchikova EG, Sharobaro VI, Ostretsova NI, Konstantinova NB. Morphological characteristics of stretched tissues when using various types of expanders. Archive of pathology. 2007;69(6):25-8.
Paramonov BA, Porembsky JO, Yablonsky VG. Burns. Guide for doctors. SPb.: Publishing house «SpetsLit»;2000.
Atiyeh BS. Nonsurgical management of hypertrophic scars: evidencebased therapies, standard practices, and emerging methods. Aesthetic. Plast. Surg. 2007;31:468-94.
Butler PD, Longaker MT, Yang GP. Current progress in keloid research and treatment. J. Am. Coll. Surg. 2008;206:731-41.
Chike-Obi CJ., Cole PD., Brissett AE. Keloids: pathogenesis, clinical features, and management. Semin Plast Surg. 2009;23:178-84.
Akhtyamov SN. Practical dermatocosmetology. Acne, acne scars and acneform dermatoses. M .: Medicine;2010.
Bogolyubov VM, editor. Physiotherapy and balneology. Book 1. M.: Publishing house «BINOM»;2008.
Ponomarenko GN, Karpova TN. Physical methods of treatment of scars. SPb.;2009.
Akaishi S, Ogawa R, Koike S. Lasertherapy forscars: scartreatmentusing long pulse Nd:YAG laser. Papers. 2009;35:46-52.
Webb C, Dyson M, Lewis WH. Stimulatory effectof 660 nm low level laserenergy onhypertrophic scar-derived fibroblast: possible mechanism forincrease incell couts. LaserSung. Med. 1988;22(5):294-301.
Shimanskaya IG, Volotavskaya AV. Methods for the correction of cicatricial changes in the skin in patients with acne. Medical cosmetology. 2015;9:42-4.
Zorin VL, Zorina AI. Qualitative and quantitative assessment of the condition of the facial skin after the use of autologous dermal fibroblasts. Bulletin of aesthetic medicine. 2011;10(2):16-28.
Cao С, Li S, Dai X et al. Genisteininhibits proliferationand functions of hyhertrophic scanfibroblasts. Burns. 2009;35(1):89-97.
Dae HK, Yuong JJ, Deok KC. Canplateletrich plasmabe used forskinrejuvenation? Evaluationof effects of platelet-rich plasmaonhumandermal fibroblast. Ann. Dermatol. 2011;23(4):424-31.
Fisher GJ, Varani J, Voorhees JJ. Looking older: fibroblastcollapse and therapeutic implications. Arch. Dermatol. 2008;144(5):666-72.
Pikuta M, Zebrowska ME, Poblocka-Olech L, Krauze-Baranowska M, Sznitowska M, Trzonkowski P. Effect of enoxaparinand onionextractonhumanskinfibroblastcell line – Therapeutic implications forthe treatmentof keloids. Pharm.Biol. 2014;52(2):262-67.
Tsepkolenko VA, Tsepkolenko AV, Karpenko ES. Phototechnologies in facial skin rejuvenation (analysis of modern technologies). Photobiology and photomedicine. 2009;2,3: 368-78.
Tsepkolenko VA.Modern algorithm for the correction of involutional-dystrophic changes in the skin. In: Fedotov VP, Makarchuk AI, editors. Clinical lectures on dermatovenerology, cosmetology and aesthetic medicine. Vol IV. Zaporozhye: «Prosvita» Publishing House; 2016. p. 368-78.
Zorina AI, Zorin VL, Cherkasov VR. Autologous dermal fibroblasts in the correction of age-related and cicatricial skin defects. Aesthetic medicine. 2011;10(2):173-79.
Zorina AI, Zorin VL, Cherkasov VR. Method of correction of age-related skin changes using autologous dermal fibroblasts. Clinical Dermatology and Venereology. 2013;3:30-7.
Perkins K, Davey RB, Walis KA. Silicone gel: anew treatmentforbums and contractures. Burns. 1982;9:406-10.
David T. Robles, Daniel Berg. Abnormal wound healing: keloids. Clinics in Dermatology. 2007;25:26-32.
Durani P, Bayat A. Levels of evidence for the treatment of keloid disease. J Plast Reconstr Aesthet Surg. 2008;61:4-17.
Fulton JE. Silicone gel sheeting for the prevention and management of evolving hypertrophic and keloid scars. Dermatol. Surg. 1995;21:947-51.
Brailovskaya TV, Fedorina TA. Morphological characteristics of the course of the wound process in experimental modeling of cut and lacerated-bruised skin wounds. Biomedicine. 2009;1:68-74.
O’Brien L, Jones DJ. Silicone gel sheeting forpreventing and treating hypertrophic and keloid scars. Cochrane Database Syst. Rev. 2013;12:9.
Van der Kerkhove E. Silicones inthe rehabilitationof burnscars: areview and overview. J. Plast. Reconstr. Aesthet. Sung. 2008;33(5):578-86.
Berman B, Flores F. Recurrence rates of excised keloids treated with postoperative triamcinolone acetonide injections or interferon alfa-2b injections. J. Am. Acad. Dermatol. 1997;37:755-57.
Asilian A, Darougheh A, Shariati F. New combinationof triamcinolone, 5-Fluorouracil, and pulsed-dye laserfortreat¬mentof keloid and hypertrophic scars. Dermatol. Surg. 2006;32:907-15.
Edwin A, Mobin S, Partha V. Keloids: a6 yearreview of the clini¬cal relevance of steroid therapy. Abstracts of 12th Congress of the EuropeanBurns Association. Budapest;2007:29.
Hochman D, Locali RF, Matsuoka PK. Intralesional triamcinolone acetonide forkeloid treatment: asystematic review. Aesth. Plast. Surg. 2008;32:705-9.
Kelemen O, Kollar L, Menuhei G. Acomparative clinical study of the treatmentof hypertrophic scars with atherintralaesional steroids orsilicone gel sheeting. Magy Seb. 2007;60(6):297-300.
Lee JH, Kim SE, Lee AY. Effects of interferon-alpha2b on keloid treatmentwith triamcinolone acetonide intralesional injection. Int. J. Dermatol. 2008;47:183-6.
Roques C, Teot L. The use of corticosteroids totreatkeloids: areview. Int. J. Low. Extrem. Wounds. 2008;7(3):137-45.
Electrophoresis of Fermencol in the Treatment of Skin Scars in Dermatology and Surgery: Methodical Recommendations. SPb.: GBOU VPO SZGMU im. I.I. Mechnikov;2012.
Kurganskaya IG, Klyuchareva SV. Restorative technologies for remodeling keloid skin scars. Bulletin of Restorative Medicine. 2011;2:43-7.
Glutkin AV. Enzymatic therapy of post-burn skin scars in young children. Surgery. Eastern Europe. 2015;3(15):114-20.
Kelly AP. Update on the management of keloids. Semin Cutan Med Surg. 2009;28(2):71-6.
Leventhal D, Furr M, Reiter D. Treatment of keloids and hypertrophic scars: a meta-analysis and review of the literature. Arch. Facial. Plast. Surg. 2006;8:362-8.
Timoshenko EV. Non-standard use of botulinum toxin type A: the possibility of preventing the formation and correction of scars. Injection methods in cosmetology. 2011;1:64-71.
Yang GP, Longaker MT. Invited Discussion: 5-Fluorouracil Treatment of Problematic Scars. Plast Reconstr Surg. 2009;123(1):139-51.
Doong H, Dissanayake S, Gowrishankar TR. Calcium antagonists alter cell shape and induce procollagenase synthesis in keloid and human dermal fibroblasts. J. Burn Care Rehabil. 1996;17:497-514.
Giugliano G, Pasquali D, Notaro A. Verapamil inhibits interleukin-6 and vascular endothelial growth factor production in primary cultures of keloid fibroblasts. J. Plast Surg. 2003;56:804-9.
Kovalevsky AA. et al. Treatment of patients with post-burn hypertrophic and keloid scars. Bulletin of Siberian Medicine. 2008;4:69-77.
Skalsky SV. Influence of verapamil on the production of pro-inflammatory cytokines by peritoneal mononuclear cells. Bulletin of the Russian Academy of Medical Sciences. 2010;3:33-5.
Border WA, Noble NA. Transforming growth factor beta in tissue fibrosi. N. Engl. J. Med. 1994;331:1286-92.
Zhang Z et al. Recombinant human decorin inhibits TGF-beta1-induced contraction of collagen lattice by hypertrophic scar fibroblasts. Burns. 2009;35:527-37.
Bush J et al. Therapies with emerging evidence efficacy: Avotermin for the improvement of scarring. Dermatol. Res. Pract. 2010;609-13.
Ferguson MW et al. Prophylactic administration of avotermin for improvement of skin scarring: three doubleblind, placebo-controlled, phase I/II studies. Lancet. 2009;373:1264-74.
Mutalik S. Treatment of keloids and hypertrophic scars. Indian J. Dermatol. Venereol. Leprol. 2005;71:3-8.
Jimenez SA, Freundlich B, Rosenbloom J. Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J. Clin. Invest. 1984;74:1112-6.
Berman B, Duncan MR. Short-term keloid treatment in vivo with human interferon alfa-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production in vitro. J. Am. Acad. Dermatol. 1989;21:694-702.
Gauglitz GG et al. Hypertrophic Scarring and Keloids: Pathomechanisms and Current and Emerging Treatment Strategies. Mol. Med. 2011;17(1-2):113-25.
Tyurenkov IN, Voronkov AV, Sliecans AA, Volotova EV. Endothelioprotectors – a new class of pharmacological drugs. Bulletin of the Russian Academy of Medical Sciences. 2012;7:50-7.
Zampieri N et al. A prospective study in children: Pre- and post-surgery use of vitamin E in surgical inci-sions. Journal of Plastic, Reconstructive & Aesthetic Surgery. 2010;63(9):1474-8.
Lorenz M et al. A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, camp-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation. J. Biol. Chem. 2004;279(7):6190-5.
Phan TT et al. Quercetin inhibits fibronectin production by keloid-derived fibroblasts. Implication for the treatment of excessive scars. J. Dermatol. Sci. 2003;33(3):192-4.
Wallerath Th et al. A blend of phenolic compounds explains the stimulatory effect of red wine on human endothelial NO synthase. Nitric Oxide. 2005;12:97-104.
Chung VQ et al. Onion extract gel versus petrolatum emollient on new surgical scars: prospective doubleb-linded study. Dermatol. Surg. 2006;32:193-7.
Jackson BA, Shelton AJ. Pilot study evaluating topical onion extract as treatment for postsurgical scars. Dermatol. Surg. 1999;25(4):267-9.
Ho WS et al. Use of onion extract, heparin, allantoin gel in prevention of scarring in Chinese patients having laser removal of tattoos: a prospective randomized controlled trial. Dermatol. Surg. 2006;32:891-6.
Beregovykh VV, Pyatigorskaya NV, Prudkevich YuA, Kedik SA. Transdermal therapeutic drug delivery systems. Vestnik Lomonosov Moscow State University of Fine Chemical Technologies. Chemistry and technology of drugs and biologically active compounds. 2012; 7(5):17-22.
Vasiliev AE, Krasnyuk II, Ravikumar S, Tokhmakhchi VN. Transdermal therapeutic systems for drug delivery (review). Chemical and Pharmaceutical Journal. 2001;35(11):29-42.
Neglur CB, Gajakosh AM. Total phenolic, falvanoid, tannin contents and antioxidant activity of organic extracts of vegetative and flowering stages of Mecardonia procumbens (Mill.) Swall. Asian J Pharm Clin Res 2021;14(9):84-6.
Joshi B, Bhandari NL, Shrestha S, Gyawali R, Thapa P. Comparative study of polyphenol, flavonoid, and antioxidant activity of various medicinal plants collected from different altitudes. Asian J Pharm Clin Res 2021;14(9):87-93.
Amjad M, Anwer Z. Antioxidant activity and total phenolic content in ripe and unpipe pomegranate (Punica Granatum L.) fruit juice. Int J Curr Pharm Res 2021;13(4):60-3.
How to Cite
Copyright (c) 2021 ILYA GULYAKIN
This work is licensed under a Creative Commons Attribution 4.0 International License.